Literature DB >> 16380613

The natural history of primary progressive MS in British Columbia, Canada.

Helen Tremlett1, Donald Paty, Virginia Devonshire.   

Abstract

BACKGROUND: Primary progressive multiple sclerosis (PPMS) has a distinct clinical phenotype and has historically been understudied with few longitudinal natural history studies spanning a reasonable time period. The authors examined patient characteristics, disease progression, and associated risk factors in the PP population of British Columbia, Canada.
METHOD: The authors report on the PP population from an upcoming publication of the natural history study of definite MS in British Columbia, Canada. The main outcome was sustained progression to Expanded Disability Status Scale (EDSS) 6, secondary outcome time to EDSS 8. Risk factors for progression included sex, onset age, onset symptoms, and for time to EDSS 8, time to EDSS 6.
RESULTS: Of the 2,837 patients with definite MS in the original study, 352 (12.4%) had PPMS. Mean disease duration was 17.2 years (0.3 to 49.6 years), mean onset age was 40.1 years (SD 11.5), and 53% (187) were female. One-quarter of the population had reached EDSS 6 after 7.3 years from onset, yet another 25% still did not require a cane after 25 years. Sex, onset age, and onset symptoms did not predict progression (p > 0.05). A shorter time to EDSS 6 predicted a shorter time to EDSS 8 (p < 0.0005). DISCUSSION: Progression of disability was slower than found in previous primary progressive multiple sclerosis natural history studies. However, considerable variation existed, with few predictors, other than "sooner to cane, sooner to wheelchair."

Entities:  

Mesh:

Year:  2005        PMID: 16380613     DOI: 10.1212/01.wnl.0000188880.17038.1d

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

Review 1.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

2.  Impact of multiple sclerosis relapses on progression diminishes with time.

Authors:  H Tremlett; M Yousefi; V Devonshire; P Rieckmann; Y Zhao
Journal:  Neurology       Date:  2009-11-04       Impact factor: 9.910

3.  SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.

Authors:  Riley Bove; Tanuja Chitnis; Bruce Ac Cree; Mar Tintoré; Yvonne Naegelin; Bernard Mj Uitdehaag; Ludwig Kappos; Samia J Khoury; Xavier Montalban; Stephen L Hauser; Howard L Weiner
Journal:  Mult Scler       Date:  2017-08-29       Impact factor: 6.312

4.  Telomere Length Is Associated with Disability Progression in Multiple Sclerosis.

Authors:  Kristen M Krysko; Roland G Henry; Bruce A C Cree; Jue Lin; Stacy Caillier; Adam Santaniello; Chao Zhao; Refujia Gomez; Carolyn Bevan; Dana L Smith; William Stern; Gina Kirkish; Stephen L Hauser; Jorge R Oksenberg; Jennifer S Graves
Journal:  Ann Neurol       Date:  2019-10-02       Impact factor: 10.422

5.  Corpus callosum damage predicts disability progression and cognitive dysfunction in primary-progressive MS after five years.

Authors:  Benedetta Bodini; Mara Cercignani; Zhaleh Khaleeli; David H Miller; Maria Ron; Sophie Penny; Alan J Thompson; Olga Ciccarelli
Journal:  Hum Brain Mapp       Date:  2012-02-13       Impact factor: 5.038

6.  Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France.

Authors:  M Debouverie; S Louis; S Pittion-Vouyovitch; T Roederer; H Vespignani
Journal:  J Neurol       Date:  2007-06-25       Impact factor: 4.849

7.  Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort.

Authors:  A Alonso; S S Jick; M J Olek; M A Hernán
Journal:  J Neurol       Date:  2007-10-01       Impact factor: 4.849

8.  Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course.

Authors:  Bahar Kaymakamzade; Ahmet Kasım Kiliç; Aslı Tuncer Kurne; Rana Karabudak
Journal:  Noro Psikiyatr Ars       Date:  2018-07-04       Impact factor: 1.339

Review 9.  Apparent changes in the epidemiology and severity of multiple sclerosis.

Authors:  Nils Koch-Henriksen; Melinda Magyari
Journal:  Nat Rev Neurol       Date:  2021-09-28       Impact factor: 42.937

10.  Predictors of Conversion to Multiple Sclerosis in Patients with Clinical Isolated Syndrome Using the 2010 Revised McDonald Criteria.

Authors:  R Alroughani; J Al Hashel; S Lamdhade; S F Ahmed
Journal:  ISRN Neurol       Date:  2012-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.